AstraZeneca PLC (ADR) (AZN) In Respiratory Drug Deal With Circassia Pharmaceuticals

In an effort to enhance collaboration with Circassia Pharmaceuticals, AstraZeneca PLC (ADR) (NYSE:AZN) has acquired an equity stake valued.....»»

Category: topSource: insidermonkeyMar 20th, 2017

Boston-based Pieris adds AstraZeneca as R&D partner in $45M deal

Shares of Pieris Pharmaceuticals soared on Wednesday after the tiny Boston biotech announced yet another collaboration with a big pharma company, this time grabbing $45 million upfront from AstraZeneca to develop inhalable respiratory disease drugs.....»»

Category: topSource: bizjournalsMay 3rd, 2017

Ionis Pharmaceuticals licences new antisense drug to AstraZeneca

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall7 hr. 46 min. ago

Indian firm a front-runner to acquire Mallinckrodt"s generic drug business: Report

India-based Intas Pharmaceuticals reportedly has emerged as a front-runner to acquire Mallinckrodt's generic drug business in a deal that could be worth $1.5 billion. Intas, the largest privately held pharmaceutical company in India, is one of two bi.....»»

Category: topSource: bizjournalsNov 2nd, 2017

Novartis to Pay $3.9 Billion for Radio-Pharmaceuticals Firm

Novartis said it has agreed to acquire Advanced Accelerator Applications for $3.9 billion, a deal that would boost its oncology portfolio as generic competition eats into sales of blockbuster blood-cancer drug Gleevec......»»

Category: smallbizSource: wsjOct 30th, 2017

Wall Street"s most hated pharma company just lost a lifeline

Markets InsiderA court ruling on Tuesday left Mallinckrodt Pharmaceuticals without protection from 11 patents on its drug Inomax, a hypoxic respiratory failure drug that made up 15% of the company's r.....»»

Category: topSource: businessinsiderSep 5th, 2017

AstraZeneca and Takeda Ink Deal to Develop Parkinson"s Drug

AstraZeneca (AZN) and Takeda Pharmaceutical Company entered into an agreement to jointly develop and .....»»

Category: personnelSource: nytAug 30th, 2017

Mystery at AstraZeneca: Is CEO Pascal Soriot Staying or Going?

Shares in the U.K. drug giant fell sharply after a news outlet reported he was moving to lead Teva Pharmaceuticals, an Israeli generics drugmaker that has been looking for a new chief for months......»»

Category: smallbizSource: wsjJul 13th, 2017

GSK"s new pharma head to join in September after AstraZeneca tussle

LONDON (Reuters) - GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca......»»

Category: topSource: reutersJun 19th, 2017

Valeant Pharmaceuticals: Bigger is Better

Though the sale of its iNova unit brings Valeant Pharmaceuticals close to meeting its goal of $5 billion in debt reduction by February 2018, the drug maker may need to step up its deal making if it wants to take a real bite out of its debt load......»»

Category: blogSource: barronsJun 8th, 2017

AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

AstraZeneca PLC AZN has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grünenthal, a German pharmaceutical company. read more.....»»

Category: blogSource: benzingaJun 8th, 2017

AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company. AstraZeneca PLC AZN has in.....»»

Category: topSource: zacksJun 8th, 2017

Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka

Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S. Teva .....»»

Category: topSource: zacksMay 16th, 2017

Pieris Pharma stock soars 54% on news of $57.5 mln AstraZeneca deal

Pieris Pharmaceuticals Inc. shares surged as much as 54% in premarket trade Wednesday on news of the company's $57.5 million deal with AstraZen.....»»

Category: topSource: marketwatchMay 3rd, 2017

Nuventra founder inks deal for new venture that could be worth as much as $49 million

A Research Triangle Park-based virtual drug development company 1st Order Pharmaceuticals (1OP) has inked a deal with Canada’s Xenon Pharmaceuticals (Nasdaq: XENE) that could be worth as much as $49 million. 1OP was founded in 2013 by Christoph.....»»

Category: topSource: bizjournalsApr 28th, 2017

Concert rebuffed $250M buyout offer from Vertex before CF drug deal

Lexington-based Concert Pharmaceuticals rebuffed a $250 million buyout offer from Vertex Pharmaceuticals in November before ultimately striking a deal earlier this month to sell a cystic fibrosis drug to the Boston company for $160 million, according t.....»»

Category: topSource: bizjournalsMar 24th, 2017

AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal

London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application .....»»

Category: topSource: zacksMar 20th, 2017

Marathon Sells Muscular-Dystrophy Drug to PTC After Pricing Scrutiny

Marathon Pharmaceuticals has struck a deal to sell its muscular dystrophy treatment to PTC Therapeutics, two weeks after a group of U.S. senators began scrutinizing the steroidal drug’s pricing......»»

Category: smallbizSource: wsjMar 16th, 2017

$160M deal with Concert helps Vertex maintain dominance in cystic fibrosis

Vertex Pharmaceuticals' move on Monday to acquire a once-a-day cystic fibrosis drug for $160 million from a 69-employee Lexington-based biotech could help the Boston company maintain its "dominant" position in the CF pharmaceuticals market, accordi.....»»

Category: topSource: bizjournalsMar 6th, 2017

Pieris Pharmaceuticals" stock soars after exclusive license deal with Japan"s ASKA

Shares of Pieris Pharmaceuticals Inc. soared 16% in premarket trade Monday, after the drug maker announced an exclusive license deal with Japan's ASKA Pharmaceutical Co. Ltd. for the development and comm.....»»

Category: topSource: marketwatchFeb 27th, 2017

MedImmune gets OK from China to pursue arthritis drug in joint venture deal

Gaithersburg-based MedImmune is expanding its footprint in China's drug market after receiving a permit to begin clinical trials there on a biologic therapy for rheumatoid arthritis. MedImmune, which is the R&D arm for London-based AstraZeneca (NYSE:.....»»

Category: topSource: bizjournalsJan 19th, 2017